Characterization of the behavioral profile of the non peptide CRF receptor antagonist GP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone

Psychopharmacology

Volumn 138, Issue 1, 1998, Pages 55-66

  Griebel, Guy ^a   Perrault, Ghislaine ^a   Sanger, David J ^a  

^a SANOFI   (France)

Author keywords

Anxiety model; Buspirone; Conflict test; CP 154,526; CRF antagonist; Defensive behavior; Diazepam; Exploration test

Indexed keywords

BUSPIRONE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIAZEPAM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DOSE RESPONSE; EXPLORATORY BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BUSPIRONE; DIAZEPAM; MALE; MICE; MICE, INBRED BALB C; PYRIMIDINES; PYRROLES; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 0031854080     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050645     Document Type: Article

References (73)

1. Adamee RE, McKay D (1993) The effects of CRF and α-helical CRF on anxiety in normal and hypophysectomized rats. J Psychopharmacol 7:346-354
2. Adamec RE, Sayin U, Brown A (1991) The effects of corticotrophin releasing factor (CRF) and handling stress on behavior in the elevated plus maze test of anxiety. J Psychopharmacol 5: 175-186
3. aldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT (1991) CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 103: 227-232
4. Barrett JE, Vanover KE (1993) 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology 112:1-12
5. Berridge CW, Dunn AJ (1986) Corticotropin-releasing factor elicits naloxone sensitive stress-induced changes of exploratory behavior in mice. Regul Pept 16:83-93
6. Berridge CW, Dunn A (1987) A corticotrophin-releasing factor antagonist reverses the stress-induced change in exploratory behavior in mice. Horm Behav 21:393-401
7. Beuzen A, Belzung C (1995) Link between emotional memory and anxiety states: a study by principal component analysis. Physiol Behav 58:111-118
8. Britton DR, Britton KT (1981) A sensitive open field measure of anxiolytic druu activity. Pharmacol Biochem Behav 15: 577-582
9. Brilton DR, Koob GF, Rivier J, Vale W (1982) Intraventricular corticotrophin-releasing factor enhances behavioral effects of novelty. Life Sci 31:363-367
10. Britton DR, Varela M, Garcia A, Rivier J (1986a) Dexamethasone suppresses pituitary adrenal but not behavioral effects of centrally administered CRF. Life Sci 38:211-216
11. Britton KT (1985) Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology 86: 170-174
12. Britton KT, Lee G, Dana R, Risch SC, Koob GF (1986b) Activating and "anxiogenic" effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci 39:1281-1286
13. Britton KT, Lee G, Vale W, Rivier J, Koob GF (1986c) Corticotropin releasing factor (CRF) receptor antagonist blocks activating and "anxiogenic" actions of CRF in the rat. Brain Res 369:303-306
14. Britton KT, McLeod S, Koob GF, Hauger R (1992) Pregnane steroid alphaxalone attenuates anxiogenic behavioral effects of corticotropin releasing factor and stress. Pharmacol Biochem Behav 41:399-403
15. Chalmers DT, Lovenberg TW, De Souza EB (1995) Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15: 6340-6350
16. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB (1996) Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 17:166-172
17. 1 receptor antauonist. J Med Chem 40: 1749-1754
18. 41. Pharmacol Biochem Behav 48:497-503
19. Cruz APM, Frei F, Graeff FG (1994) Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171-176
20. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
21. Dunn AJ, File SE (1987) Corticotropin releasing factor has an anxiogenic action in the social interaction test. Horm Behav 21: 193-202
22. Eaves M, Britton KT, Rivier J, Vale W, Koob GF (1985) Effects of corticotropin releasing factor in locomotor activation in hypophysectomized rats. Peptides 6:923-926
23. Ehlers C, Henriksen S, Wang M, Rivier J, Vale WW, Bloom FE (1983) Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res 278:332-336
24. File SE, Johnston AL, Baldwin HA (1988) Anxiolytic and anxiogenic drugs: changes in behaviour and endocrine responses. Stress Med 4:221-230
25. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319-395
26. Griebel G, Belzung C, Misslin R, Vogel E (1993) The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav Pharmacol 4:637-644
27. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995a) A model of "antipredator" defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 6:732-745
28. 2A antagonist pirenperone. Pharmacol Biochem Behav 51:235-244
29. Griebel G, Blanchard DC, Blanchard RJ (1996a) Predator-elicited flight responses in Swiss-Webster an experimental model of panic attacks. Prog Neuro-Psychopharmacol Biol Psychiatry 20:185-205
30. Griebel G, Sanger DJ, Perrault G (1996b) Further evidence for differences between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety. Neuropharmacology 35:1081-1091
31. Griebel G, Sanger DJ, Perrault G (1996e) The mouse defense test battery: evaluation of the effects of non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Behav Pharmacol 7:560-572
32. Griebel G, Blanchard DC, Blanchard RJ ( 1996d) Evidence that the behaviors in the mouse defense test battery relate to different emotional states: a factor analytic study. Physiol Behav 60:1255-1260
33. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1997a) Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav 57:817-827
34. Griebel G, Sanger DJ, Perrault G (1997b) Genetic differences in the mouse defense test battery. Aggress Behav 23:19-31
35. Griebel G, Perrault G, Sanger DJ (1997c) Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology 131: 180-186
36. Handley SL (1995) 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 66:103-148
37. Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF (1992) Corticotropin releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 581:190-197
38. Kalin NH, Sherman JE. Takahashi LK (1988) Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res 457:130-135
39. Koob GF (1991) Behavioral responses to stress - focus on corticotropin-releasing factor. In: Brown MR, Koob GF, Rivier C (eds) Stress, neurobiology and neuroendocrinology. Dekker, New York, pp 255-271
40. Levine AS, Rogers B, Kneip J, Grace M, Morley JE (1983) Effect of centrally administered corticotropin releasing factor (CRF) on multiple feeding paradigms. Neuropharmacology 22:337-339
41. Liang KC, Melia KR, Miserendino MJ, Falls WA, Campeau S, Davis M (1992) Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 12: 2303-2312
42. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 59:229-239
43. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau JL (1996) A non-peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309: 195-200
44. Makino J, Kato K, Maes FW (1991) Temporal structure of open-field behavior in inbred strains of mice. Jpn Psychol Res 33:145-152
45. 1 receptor antagonist. Eur J Pharmacol 323:21-26
46. Menzaghi F, Howard RL, Heinrichs SC, Vale W, Rivier J, Koob GF (1994) Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 269:564-572
47. Misslin R, Cigrang M (1986) Does neophobia necessarily imply fear or anxiety? Behav Proc 12:45-50
48. Misslin R, Belzung C, Vogel E (1989) Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav Proc 8:119-132
49. Morley JE, Levine AS (1983) Corticotrophin-releasing factor, grooming and ingestive behavior. Life Sci 81:1459-1464
50. Orth DN (1992) Corticotropin-releasing hormone in humans. Endocrine Rev 13:164-191
51. Parmigiani S, Brain PF, Palanza P (1989) Ethoexperimental analysis of different forms of intraspecific aggression in the house mouse. In: Blanchard RJ, Brain PF, Blanchard DC, Parmigiani S (eds) Ethoexperimental approaches to the study of behavior. Kluwer, Dordrecht, pp 418-431
52. Peeler DF, Nowakowsky RS (1987) Genetic factors and the measurement of exploratory activity. Behav Neural Biol 48:90-103
53. Fellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167
54. Rickels K. Weisman K, Norstad N. Singer M, Stoltz D, Brown A, Danton J (1982) Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 43:81-86
55. Rivier J, Rivier C, Vale WW (1984) Synthetic competitive antagonists of corticotrophin-releasing factor: effects on ACTH secretion in the rat. Science 244:889-891
56. Robertson HA (1979) Benzodiazepine receptors in "emotional" and "non-emotional" mice: Comparison of four strains. Eur J Pharmacol 56:163-166
57. Rodgers RJ, Cole JC (1994) The elevated plus maze: pharmacology, methodology and ethology. In: Cooper SJ. Hendrie CA (eds) Ethology and psychopharmacology. Wiles, Chichester, pp 9-44
58. Roy Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP. Gold PW (1986) The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143:896-899
59. Sanger DJ (1992) Increased rates of punished responding produced by buspirone-like compounds in rats. J Pharmacol Exp Ther 261:513-517
60. Sanger DJ, Joly D, Zivkovic B (1985) Behavioral effects of non-benzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide. J Pharmacol Exp Ther 232:831-837
61. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD, III. Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482
62. Sherman JE, Kalin NH (1987) The effects of ICV-CRH on novelty-induced behavior. Pharmacol Biochem Behav 26:699-703
63. Smagin GN, Harris RBS, Ryan DH (1996) Corticotropin releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress induced defensive withdrawal in rats. Neurosci Lett 220:167-170
64. Spadaro F, Berridge CW, Baldwin HA, Dunn AJ (1990) Corticotropin-releasing factor acts via a third ventricle site to reduce exploratory behavior in rats. Pharmacol Biochem Behav 36:305-309
65. Stenzel-Poore MP, Duncan JE, Rittenberg MB, Bakke AC, Heinrichs SC (1996) CRH overproduction in transgenic mice: behavioral and immune system modulation. Ann NY Acad Sci 780:36-48
66. Simon RE, Koob GR, le Moal M, Rivier J, Vale W (1982) Corticotropin releasing factor (CRF) produces behavioral activation in rats. Nature 297:331-333
67. Swerdlow NR, Geyer MA, Vale WW, Koob GF (1986) Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 88:147-152
68. 41. Neuropsychopharmacology 2:285-292
69. Takahashi LK, Kalin NH, Vanden Burgt JA, Sherman JE (1989) Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav Neurosci 103:648-654
70. Tazi A, Swerdlow NR, le Moal M, Rivier J, Vale WW, Kooh GF (1987) Behavioral activation of CRF: evidence for the involvement of the ventral forebrain. Life Sci 41:41-50
71. Vale WW, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 213: 1394-1397
72. Vale WW, Rivier C, Brown MR, Spiess J, Koob G, Swanson L, Bilezikjian L, Bloom F, Rivier J (1983) Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 39:245-270
73. Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1-7